OnCore Login

Return to Trial Database

HCRN-GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Status

Enrollment Closed

Cancer Type(s)

Bladder

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Publications

Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC)
  • MD Galsky, S Daneshmand, KG Chan, TB Dorff, JP Cetnar, B O'Neil, A D'souza, R Mamtani, C Kyriakopoulos, P Garcia, S Izadmehr, M Yu, Q Zhao, R Mehrazin, SC Lewis, J Sfakianos, SK Pal
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
  • M Galsky, S Daneshmand, S Izadmehr, E Gonzalez-Kozlova, K Chan, S Lewis, B El Achkar, T Dorff, J Paul Cetnar, B Neil, A D’Souza, R Mamtani, C Kyriakopoulos, T Jun, M Gogerly-Moragoda, R Brody, H Xie, K Nie, G Kelly, A Horwitz, Y Kinoshita, E Ellis, Y Nose, G Ioannou, R Cabal, G Kenneth Haines, L Wang, K Mouw, R Samstein, R Mehrazin, N Bhardwaj, M Yu, Q Zhao, S Kim-Schulze, R Sebra, J Zhu, S Gnjatic, J Sfakianos, S K. Pal

Trial Locations

All sites in which the trial HCRN-GU16-257 being conducted in.
City of Hope
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Knight Cancer Institute at Oregon Health & Science University
Penn Medicine Abramson Cancer Center
University of Wisconsin Carbone Cancer Center
USC Norris Comprehensive Cancer Center
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278